A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Acne Vulgaris
Interventions
DRUG

Low Strength IDP-107

Once a day for 16 weeks

DRUG

High Strength IDP-107

Once a day for 16 weeks

DRUG

Placebo

Once a day for 16 weeks

Trial Locations (20)

32174

Ameriderm Research, Ormond Beach

32204

North Florida Dermatology Associates, PA, Jacksonville

33175

FXM Research Corp., Miami

42301

Pedia Research LLC, Owensboro

46168

The Indiana Clinical Trials Center, PC, Plainfield

46256

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

48059

Hamzavi Dermatology, Fort Gratiot

55432

Minnesota Clinical Study Center, Fridley

78759

DermResearch, Inc., Austin

80220

Horizons Clinical Research Center, LLC, Denver

84088

South Valley Dermatology, West Jordan

84124

Dermatology Research Center, Inc., Salt Lake City

92056

Dermatology Specialists, Inc., Oceanside

97210

Oregon Dermatology and Research Center, Portland

99204

Premier Clinical Research, Spokane

01830

ActivMed Practices and Research, Inc., Haverhill

08009

Comprehensive Clinical Research, Berlin

L4M 6L2

Ultranova Skincare, Barrie

L4B 1A5

The Centre for Dermatology and Cosmetic Surgery, Richmond Hill

N2J 1C4

K. Papp Clinical Research, Waterloo

Sponsors
All Listed Sponsors
lead

Dow Pharmaceutical Sciences

INDUSTRY